Caseware UK (AP4) 2024.0.164 2024.0.164 2025-08-31 2025-08-31 2026-05-14 2024-09-01 false Development of technology in the healthcare sector 2 2 true true The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. false 15088749 2024-09-01 2025-08-31 15088749 2023-08-22 2024-08-31 15088749 2025-08-31 15088749 2024-08-31 15088749 c:Director1 2024-09-01 2025-08-31 15088749 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-08-31 15088749 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-08-31 15088749 d:CurrentFinancialInstruments 2025-08-31 15088749 d:CurrentFinancialInstruments 2024-08-31 15088749 d:CurrentFinancialInstruments d:WithinOneYear 2025-08-31 15088749 d:CurrentFinancialInstruments d:WithinOneYear 2024-08-31 15088749 d:ShareCapital 2024-09-01 2025-08-31 15088749 d:ShareCapital 2025-08-31 15088749 d:ShareCapital 2023-08-22 2024-08-31 15088749 d:ShareCapital 2024-08-31 15088749 d:RetainedEarningsAccumulatedLosses 2024-09-01 2025-08-31 15088749 d:RetainedEarningsAccumulatedLosses 2025-08-31 15088749 d:RetainedEarningsAccumulatedLosses 2024-08-31 15088749 c:FRS102 2024-09-01 2025-08-31 15088749 c:AuditExempt-NoAccountantsReport 2024-09-01 2025-08-31 15088749 c:FullAccounts 2024-09-01 2025-08-31 15088749 c:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 15088749 d:DevelopmentCostsCapitalisedDevelopmentExpenditure d:ExternallyAcquiredIntangibleAssets 2024-09-01 2025-08-31 15088749 2 2024-09-01 2025-08-31 15088749 e:PoundSterling 2024-09-01 2025-08-31 iso4217:GBP xbrli:pure

Registered number: 15088749 HEALTHFINDER TECH LIMITED UNAUDITED FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE PERIOD ENDED 31 AUGUST 2025 FLETCHER & PARTNERS CHARTERED ACCOUNTANTS SALISBURY
HEALTHFINDER TECH LIMITED REGISTERED NUMBER:15088749
BALANCE SHEET AS AT 31 AUGUST 2025
|  | 2025 |  | 2024
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Intangible assets | 4 |  | 89,075 |  | 60,429
|  |  | 89,075 |  | 60,429
Current assets |  |  |  |  |
Cash at bank and in hand | 5 | 2,071 |  | 12,191 |
|  | 2,071 |  | 12,191 |
Creditors: amounts falling due within one year | 6 | (92,585) |  | (72,520) |
Net current liabilities |  |  | (90,514) |  | (60,329)
Total assets less current liabilities |  |  | (1,439) |  | 100
Net (liabilities)/assets |  |  | (1,439) |  | 100
Capital and reserves |  |  |  |  |
Called up share capital |  |  | 100 |  | 100
Profit and loss account |  |  | (1,539) |  | -
|  |  | (1,439) |  | 100
The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf on 14 May 2026.
Mr Michael Arnold
Director
The notes on pages 4 to 6 form part of these financial statements. Page 1
HEALTHFINDER TECH LIMITED
STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 31 AUGUST 2025
| Called up share capital | Profit and loss account | Total equity
| £ | £ | £
At 1 September 2024 | 100 | - | 100
Comprehensive income for the period |  |  |
Loss for the period | - | (1,539) | (1,539)
Other comprehensive income for the period | - | - | -
Total comprehensive income for the period | - | (1,539) | (1,539)
Total transactions with owners | - | - | -
At 31 August 2025 | 100 | (1,539) | (1,439)
| The notes on pages 4 to 6 form part of these financial statements.
Page 2
HEALTHFINDER TECH LIMITED
STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 31 AUGUST 2024
| Called up share capital | Total equity
| £ | £
Other comprehensive income for the period | - | -
Total comprehensive income for the period | - | -
Contributions by and distributions to owners |  |
Shares issued during the period | 100 | 100
Total transactions with owners | 100 | 100
At 31 August 2024 | 100 | 100
| The notes on pages 4 to 6 form part of these financial statements.
Page 3
HEALTHFINDER TECH LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 AUGUST 2025
1. | General information
Healthfinder Tech Limited is a private company limited by shares incorporated in England and Wales number 15088749 registered office First Floor, Highfield House, Bartons Road, Fordingbridge, Hampshire SP6 1JD. Its principal activity is the development and application of software in the health care sector. 2. Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. The following principal accounting policies have been applied:
| 2.2 | Research and development
In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years. If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.
| 2.3 | Interest income
Interest income is recognised in profit or loss using the effective interest method.
| 2.4 | Intangible assets
Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.
| 2.5 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.6 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Page 4
HEALTHFINDER TECH LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 AUGUST 2025
3. | Employees
| The average monthly number of employees, including the directors, during the period was as follows:
|  |  | 31 August | Period ended 31 August
|  |  | 2025 | 2024
|  |  | No. | No.
|  | Directors | 2 | 2
4. | Intangible assets
|  | Developm't expenditure
|  | £
| Cost |
| At 1 September 2024 | 60,429
| Additions | 28,646
| At 31 August 2025 | 89,075
| Net book value |
| At 31 August 2025 | 89,075
| At 31 August 2024 | 60,429
5. | Cash and cash equivalents
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Cash at bank and in hand | 2,071 | 12,191
|  | 2,071 | 12,191
Page 5
HEALTHFINDER TECH LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 AUGUST 2025
6. | Creditors: Amounts falling due within one year
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Other taxation and social security | - | 20
| Other creditors | 91,050 | 72,500
| Accruals and deferred income | 1,535 | -
|  | 92,585 | 72,520
7. | Related party transactions
| ''Other creditors' comprises a loan of £87,150 from the director Mr M Arnold and £4,000 from the director Dr S Dharmasiri which are unsecured, interest-free and repayable on demand.
Page 6